| __timestamp | MannKind Corporation | Verona Pharma plc |
|---|---|---|
| Wednesday, January 1, 2014 | 79383000 | 1802274 |
| Thursday, January 1, 2015 | 108402000 | 2512761 |
| Friday, January 1, 2016 | 46928000 | 2894488 |
| Sunday, January 1, 2017 | 74959000 | 8096274 |
| Monday, January 1, 2018 | 79716000 | 7985229 |
| Tuesday, January 1, 2019 | 74669000 | 8994597 |
| Wednesday, January 1, 2020 | 59040000 | 29772000 |
| Friday, January 1, 2021 | 77417000 | 33907000 |
| Saturday, January 1, 2022 | 91473000 | 26579000 |
| Sunday, January 1, 2023 | 94314000 | 49868547 |
Data in motion
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Verona Pharma plc and MannKind Corporation, from 2014 to 2023. Over this period, MannKind consistently outspent Verona, with SG&A expenses peaking at approximately $94 million in 2023, a 20% increase from 2014. In contrast, Verona's expenses surged by over 2,600%, reaching nearly $50 million in 2023. This dramatic rise reflects Verona's aggressive expansion and strategic investments. The data highlights MannKind's steady financial strategy, while Verona's exponential growth underscores its ambitious market positioning. Such insights are invaluable for investors and stakeholders aiming to navigate the competitive landscape of the pharmaceutical sector.
Who Optimizes SG&A Costs Better? AbbVie Inc. or Verona Pharma plc
Breaking Down SG&A Expenses: Intra-Cellular Therapies, Inc. vs Verona Pharma plc
Operational Costs Compared: SG&A Analysis of BioMarin Pharmaceutical Inc. and Verona Pharma plc
Selling, General, and Administrative Costs: Madrigal Pharmaceuticals, Inc. vs Verona Pharma plc
Who Optimizes SG&A Costs Better? Madrigal Pharmaceuticals, Inc. or MannKind Corporation
SG&A Efficiency Analysis: Comparing Axsome Therapeutics, Inc. and MannKind Corporation
Who Optimizes SG&A Costs Better? Verona Pharma plc or MorphoSys AG
Who Optimizes SG&A Costs Better? Verona Pharma plc or Supernus Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for CymaBay Therapeutics, Inc. and MannKind Corporation
Comparing SG&A Expenses: Viking Therapeutics, Inc. vs MannKind Corporation Trends and Insights
MannKind Corporation and Celldex Therapeutics, Inc.: SG&A Spending Patterns Compared
MannKind Corporation and Dynavax Technologies Corporation: SG&A Spending Patterns Compared